MedTrace Logo

AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184

NCT01824446 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-06-24

Study results available
· View outcomes & findings →

Summary

To evaluate how the body absorbs, metabolizes (breaks down) and excretes (eliminates) the study drug. Further, the study will determine how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it when given as a single dose to healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

Radiolabeled SPD602 (FBS0701, SSP-004184)

A single oral dose of 3g of radio-labelled SSP-004184 on Day 1

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-01
Primary Completion
2013-05-29
Completion
2013-05-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01824446 on ClinicalTrials.gov